Zobrazeno 1 - 10
of 1 117
pro vyhledávání: '"cdk4/6 inhibitor"'
Autor:
Chaoji Shi, Houyu Ju, Rong Zhou, Shengming Xu, Yunteng Wu, Ziyue Gu, Ying Wang, Wanling Chen, Xinyi Huang, Yong Han, Shuyang Sun, Chuwen Li, Min Wang, Guoyu Zhou, Zhiyuan Zhang, Jiang Li, Guoxin Ren
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Mucosal melanoma (MM) is a rare but devastating subtype of melanoma. Our previous studies have demonstrated robust anti-tumor effects of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in head and neck MM (HNMM) patient-derived x
Externí odkaz:
https://doaj.org/article/3608e6a7d46a46419f19925324cee8c7
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is currently the standard first-line treatment for patients with metastatic hormone receptor positive (HR+), and HER2-negative (HER2-) breast cancer. However, the imp
Externí odkaz:
https://doaj.org/article/1a0bc4e2c8114dada25edcc421f7745c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Objective: Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (abemaciclib, palbociclib and ribociclib) have been recommended in the first-line treatment of hormone receptor-positive (HR+) breast cancer in China. Our study aims to evaluate the efficacy
Externí odkaz:
https://doaj.org/article/0a4ef77523b74d41b2dd5a19467243a7
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are first-line treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With their increasing clinical use, infection-related adverse eve
Externí odkaz:
https://doaj.org/article/d3d9febf06b94f71bcc2ae6139dca011
Autor:
Wenyan Gao, Shi Liu, Yenan Wu, Wenqing Wei, Qi Yang, Wenxin Li, Hongyan Chen, Aiping Luo, Yanfeng Wang, Zhihua Liu
Publikováno v:
EBioMedicine, Vol 105, Iss , Pp 105177- (2024)
Summary: Background: The 5-year survival rate of oesophageal squamous cell carcinoma (ESCC) is approximately 20%. The prognosis and drug response exhibit substantial heterogeneity in ESCC, impeding progress in survival outcomes. Our goal is to identi
Externí odkaz:
https://doaj.org/article/1f40561bef53427695c0b27caa9c6d1c
Autor:
Huiyue Li, Yun Wu, Haotian Zou, Salil Koner, Jennifer K. Plichta, Sara M. Tolaney, Jian Zhang, You-Wen He, Qingyi Wei, Li Tang, Hui Zhang, Baoshan Zhang, Yuanyuan Guo, Xin Chen, Kan Li, Liyou Lian, Fei Ma, Sheng Luo
Publikováno v:
EBioMedicine, Vol 105, Iss , Pp 105186- (2024)
Summary: Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with traditional endocrine therapy (ET) are now the recommended first-line treatment for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (MB
Externí odkaz:
https://doaj.org/article/a88a4058f89f47909933524af7e014a0
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-11 (2024)
Abstract BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70–80% of BRCA2-mutated BC are estrogen rece
Externí odkaz:
https://doaj.org/article/6a037b966168452995fc1f3e3996b25d
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102092- (2024)
CDK4/6 inhibitors combined with endocrine therapy prolonged survival in hormone receptor (HR)-positive and HER2-negative advanced breast cancer. We investigated whether CDK4/6 inhibitors enhance radiosensitivity and their underlying mechanisms of thi
Externí odkaz:
https://doaj.org/article/1de44e4112724428b5c89026680f9140
Autor:
Anna Hester, Franziska Henze, Anna Marie Debes, Charlotte Leonie Schubert, Alexander Koenig, Nadia Harbeck, Rachel Wuerstlein
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundSince the European approval of CDK4/6 inhibitors in 2016, the treatment of patients with hormone-receptor-positive, HER2-negative metastatic breast cancer has changed significantly. Compared with chemotherapy, endocrine-based therapy has di
Externí odkaz:
https://doaj.org/article/66d7d0cb722749a39c3051bc33a39db6
Autor:
Chuntao Quan, Zhijie Wu, Juan Xiong, Manqing Li, Yu Fu, Jiaying Su, Yue Wang, Lvwen Ning, Deju Zhang, Ni Xie
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-21 (2023)
Abstract Background Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant clinical prospects in t
Externí odkaz:
https://doaj.org/article/a5d91d0d1ba44325850be52c41d08049